- Home
- XPL vs LUNG Comparison
XPL vs LUNG Comparison
Compare XPL & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPL
- LUNG
- Stock Information
- Founded
- XPL 1984
- LUNG 1995
- Country
- XPL United States
- LUNG United States
- Employees
- XPL N/A
- LUNG N/A
- Industry
- XPL Precious Metals
- LUNG Industrial Specialties
- Sector
- XPL Basic Materials
- LUNG Health Care
- Exchange
- XPL Nasdaq
- LUNG Nasdaq
- Market Cap
- XPL 62.5M
- LUNG 65.6M
- IPO Year
- XPL N/A
- LUNG 2020
- Fundamental
- Price
- XPL $0.78
- LUNG $1.65
- Analyst Decision
- XPL Strong Buy
- LUNG Buy
- Analyst Count
- XPL 2
- LUNG 7
- Target Price
- XPL $1.20
- LUNG $7.66
- AVG Volume (30 Days)
- XPL 605.8K
- LUNG 246.9K
- Earning Date
- XPL 11-07-2025
- LUNG 10-29-2025
- Dividend Yield
- XPL N/A
- LUNG N/A
- EPS Growth
- XPL N/A
- LUNG N/A
- EPS
- XPL N/A
- LUNG N/A
- Revenue
- XPL N/A
- LUNG $90,549,000.00
- Revenue This Year
- XPL N/A
- LUNG $10.30
- Revenue Next Year
- XPL N/A
- LUNG $14.72
- P/E Ratio
- XPL N/A
- LUNG N/A
- Revenue Growth
- XPL N/A
- LUNG 18.24
- 52 Week Low
- XPL $0.54
- LUNG $1.47
- 52 Week High
- XPL $0.90
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- XPL 55.19
- LUNG 49.27
- Support Level
- XPL $0.68
- LUNG $1.52
- Resistance Level
- XPL $0.86
- LUNG $1.69
- Average True Range (ATR)
- XPL 0.07
- LUNG 0.08
- MACD
- XPL 0.01
- LUNG 0.01
- Stochastic Oscillator
- XPL 55.80
- LUNG 50.91
About XPL Solitario Resources Corp.
Solitario Resources Corp is exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. It has joint venture interests in large, high-grade zinc development projects. The Florida Canyon Zinc Project in Peru is a development asset held jointly with Nexa Resources S.A., Golden Crest Project in South Dakota and the Lik Zinc Project represents a large-tonnage, high-grade development project in Alaska in partnership with Teck Resources. In addition, the company has an additional portfolio of exploration properties and royalties in the Americas.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.